283 related articles for article (PubMed ID: 34252309)
1. Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.
Poirel L; Sadek M; Nordmann P
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0087721. PubMed ID: 34252309
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3.
Malik S; Kaminski M; Landman D; Quale J
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868330
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
4.
Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
[TBL] [Abstract][Full Text] [Related]
5. Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability.
Stracquadanio S; Bonomo C; Marino A; Bongiorno D; Privitera GF; Bivona DA; Mirabile A; Bonacci PG; Stefani S
Microbiol Spectr; 2022 Oct; 10(5):e0234722. PubMed ID: 36173300
[TBL] [Abstract][Full Text] [Related]
6. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of PER-1-Mediated Cefiderocol Resistance and Synergistic Inhibition of PER-1 by Cefiderocol in Combination with Avibactam or Durlobactam in Acinetobacter baumannii.
Liu X; Lei T; Yang Y; Zhang L; Liu H; Leptihn S; Yu Y; Hua X
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0082822. PubMed ID: 36377939
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Cefiderocol, a Novel Siderophore Cephalosporin, against Multidrug Resistant Acinetobacter baumannii Clinical Isolates in Japan.
Kimura Y; Hatayama N; Sato Y; Nishida S; Yoshino Y
Jpn J Infect Dis; 2024 May; 77(3):178-181. PubMed ID: 38296540
[TBL] [Abstract][Full Text] [Related]
9. Contribution of Iron-Transport Systems and β-Lactamases to Cefiderocol Resistance in Clinical Isolates of Acinetobacter baumannii Endemic to New York City.
Asrat H; Samaroo-Campbell J; Ata S; Quale J
Antimicrob Agents Chemother; 2023 Jun; 67(6):e0023423. PubMed ID: 37212653
[TBL] [Abstract][Full Text] [Related]
10.
Abdul-Mutakabbir JC; Nguyen L; Maassen PT; Stamper KC; Kebriaei R; Kaye KS; Castanheira M; Rybak MJ
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0264620. PubMed ID: 34125590
[TBL] [Abstract][Full Text] [Related]
11. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.
Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP
Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan.
Yamano Y; Ishibashi N; Kuroiwa M; Takemura M; Sheng WH; Hsueh PR
J Glob Antimicrob Resist; 2022 Mar; 28():120-124. PubMed ID: 34958997
[TBL] [Abstract][Full Text] [Related]
13. Role of β-lactamase inhibitors on cefiderocol activity against carbapenem-resistant Acinetobacter species.
Mezcord V; Wong O; Pasteran F; Corso A; Tolmasky ME; Bonomo RA; Ramirez MS
Int J Antimicrob Agents; 2023 Jan; 61(1):106700. PubMed ID: 36470509
[No Abstract] [Full Text] [Related]
14. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
[TBL] [Abstract][Full Text] [Related]
15. ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and
Jacobs MR; Abdelhamed AM; Good CE; Rhoads DD; Hujer KM; Hujer AM; Domitrovic TN; Rudin SD; Richter SS; van Duin D; Kreiswirth BN; Greco C; Fouts DE; Bonomo RA
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323050
[TBL] [Abstract][Full Text] [Related]
16. Activity of Cefiderocol Against
Iregui A; Khan Z; Landman D; Quale J
Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia.
Alzayer M; Alghoribi MF; Alalwan B; Alreheli A; Aljohani S; Bosaeed M; Doumith M
J Glob Antimicrob Resist; 2023 Mar; 32():176-180. PubMed ID: 36481491
[TBL] [Abstract][Full Text] [Related]
18. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
[TBL] [Abstract][Full Text] [Related]
19. A Selective Culture Medium for Screening Cefiderocol Resistance in
Ibrahim A; Bouvier M; Sadek M; Decousser JW; Poirel L; Nordmann P
J Clin Microbiol; 2023 Jul; 61(7):e0188322. PubMed ID: 37338403
[TBL] [Abstract][Full Text] [Related]
20. Antibacterial spectrum of cefiderocol.
Gijón Cordero D; Castillo-Polo JA; Ruiz-Garbajosa P; Cantón R
Rev Esp Quimioter; 2022 Sep; 35 Suppl 2(Suppl 2):20-27. PubMed ID: 36193981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
